NRXS — NeurAxis, Inc.

NeurAxis, Inc. (NRXS) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Revenues: $968,000, a 27% increase from $761,000 in Q4 2024.
• Full-Year 2025 Revenues: $3.6 million, up 33% from $2.7 million in 2024.
• Unit Deliveries: Increased by 35% in Q4 and 44% for the full year, driven by patients with full reimbursement health insurance.
• Gross Margin: 85.4% in Q4 2025, down from 86.4% in Q4 2024; full-year gross margin at 84.2%, down from 86.5% in 2024.
• Operating Loss: $1.7 million in Q4 2025, an increase of 17% year-over-year; full-year operating loss of $7.8 million, a 9% increase from 2024.
• Cash Position: $5 million as of December 31, 2025, with an improved liquidity position of over $6 million in 2026 after raising an additional $2.6 million.

2. Strategic Updates and Business Highlights

• Commercialization Strategy: Focused on the IV Stem neuromodulation technology for pediatric and adult populations, with a successful rollout of a Category I CPT code effective January 1, 2026.
• Insurance Coverage: Secured coverage for approximately 45 million lives from a major national health insurer, enhancing reimbursement access.
• Operational Focus: Aimed at expanding medical policy coverage and increasing commercial footprint, particularly in children's hospitals and the Veterans Administration (VA) system.
• Clinical Trials: Initiated a randomized controlled trial for adult patients with functional dyspepsia at the Cleveland Clinic, and ongoing studies for cyclic vomiting syndrome and post-operative pain.

3. Forward Guidance and Outlook

• Q1 2026 Expectations: Anticipated revenue growth driven by the new CPT code and increased patient submissions, with a focus on closing gaps in insurance coverage.
• Long-Term Growth: Management believes the company is positioned for a multi-year growth cycle, with a disciplined, data-driven approach to expanding market presence and operational capabilities.

4. Challenges and Points of Concern

• Prior Authorization Issues: While submission rates for prior authorizations have increased significantly, approval rates remain low, indicating ongoing challenges in gaining full access to patient populations.
• Dependence on Insurance Coverage: The need for written policy coverage remains critical, as payers do not provide coverage based solely on the CPT code.
• Operational Hurdles: Hospitals face internal barriers related to scheduling and staffing, which may slow the adoption of IV Stem treatments.
• Gross Margin Decline: The decrease in gross margins due to increased discounting and inventory obsolescence raises concerns about profitability moving forward.

5. Notable Q&A Insights

• Prior Authorization Trends: Management reported a 10x increase in prior authorization submissions since the introduction of the CPT code, but emphasized that approval rates are still low.
• Utilization Trends: Hospitals with strong insurance coverage and dedicated IV Stem clinic time are performing well, but many hospitals are not treating patients due to incomplete payer coverage.
• Hiring Plans: The company plans to hire additional staff to support commercial efforts, particularly as adoption grows within the VA system and children's hospitals.
• Adult Market Potential: While adult coverage is not expected in the near term, ongoing studies and positive feedback from adult gastroenterologists indicate potential for future growth in this segment.

Overall, NeurAxis is optimistic about its growth trajectory, bolstered by recent strategic milestones, but faces significant challenges related to insurance coverage and operational execution.